Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

B. G. Weinshenker, M. Issa and J. Baskerville
Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.

BACKGROUND: The anticipated rate of short-term worsening of disability scores is the basis of power estimations in clinical trials of progressive multiple sclerosis (MS). While the clinician is most concerned in modifying the long-term outcome (eg, time to reach the Expanded Disability Status Scale [EDSS]6), the end points studied in clinical trials are those describing short-term outcome (eg, worsening of EDSS scores over 1 to 3 years). However, short-term outcome of MS may not be correlated with long-term outcome. OBJECTIVES: To validate previously published models predicting time to EDSS 6. To establish predictors of short-term outcome of MS. SETTING: The Ottawa, Ontario, Regional Multiple Sclerosis Clinic. PATIENTS: Two hundred fifty-nine patients were followed up prospectively by a single neurologist. MAIN OUTCOME MEASURES: Actuarial analysis of time to reach EDSS 6 and change in EDSS scores over a follow-up period of 1 to 3 years. RESULTS: The long-term outcome in the Ottawa population was more favorable than published data from London, Ontario. Predictions of time to EDSS 6 were not strongly correlated with the degree of short-term worsening over the follow-up period. Parameters associated with a higher probability of short-term worsening were proximity of the baseline EDSS score to 4.5 and duration of MS less than 20 years. CONCLUSION: Baseline EDSS and duration of MS must be considered in the design of clinical trials of progressive MS.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis
Hirst et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:1137-1143.
ABSTRACT | FULL TEXT  

The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Minden et al.
Mult Scler 2006;12:24-38.
ABSTRACT  

Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease
Pittock et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:1693-1697.
ABSTRACT | FULL TEXT  

Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis
Rio et al.
Mult Scler 2005;11:306-309.
ABSTRACT  

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis
Eriksson et al.
Mult Scler 2003;9:260-274.
ABSTRACT  

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis
Scott et al.
Mult Scler 2003;9:289-292.
ABSTRACT  

Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: A prospective case-controlled study
Alusi et al.
Brain 2001;124:1576-1589.
ABSTRACT | FULL TEXT  

A study of tremor in multiple sclerosis
Alusi et al.
Brain 2001;124:720-730.
ABSTRACT | FULL TEXT  

Short-term prognosis in early relapsing-remitting multiple sclerosis
Scott et al.
Neurology 2000;55:689-693.
ABSTRACT | FULL TEXT  

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts
Liu and Blumhardt
J. Neurol. Neurosurg. Psychiatry 2000;68:450-457.
ABSTRACT | FULL TEXT  

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice et al.
Neurology 2000;54:1145-1155.
ABSTRACT | FULL TEXT  

Glutathione S-transferase polymorphisms in MS: Their relationship to disability
Mann et al.
Neurology 2000;54:552-552.
ABSTRACT | FULL TEXT  

Tremor in multiple sclerosis
ALUSI et al.
J. Neurol. Neurosurg. Psychiatry 1999;66:131-134.
FULL TEXT  

Determinants of Gd-enhanced MRI response to IFN-{beta}-1a treatment in relapsing-remitting multiple sclerosis
Koudriavtseva et al.
Mult Scler 1998;4:403-407.
ABSTRACT